CD19 / FcγRIIb

Class

Fc-engineered monoclonal antibody (obexelimab; binds CD19 while co-engaging the inhibitory FcγRIIb receptor)

Pathway

B-cell/plasmablast inhibitory co-engagement (non-depleting)

CD19 is a surface protein expressed across most stages of B-cell development that amplifies signaling through the B-cell receptor (BCR), promoting B-cell activation, proliferation, and eventual antibody production. FcγRIIb is a distinct receptor on B cells that normally acts as a brake, dampening BCR-driven activation when engaged. This mechanism uses an antibody engineered to bind CD19 while simultaneously engaging FcγRIIb with high affinity, bringing the two receptors into proximity on the same cell. Rather than killing or removing B cells, as many antibodies directed at B-cell surface markers do, this approach delivers an inhibitory signal directly into the B-cell signaling pathway, reducing activation without depleting the cell population. The rationale for combining CD19 targeting with FcγRIIb engagement is that CD19 provides broad access to B cells and their more mature antibody-secreting descendants, plasmablasts, while FcγRIIb supplies the inhibitory instruction; neither target alone would achieve this reversible dampening effect. This non-depleting strategy is of interest in autoimmune conditions where B cells and plasmablasts drive disease through autoantibody production, such as lupus and related antibody-mediated disorders, offering a way to modulate humoral immune activity while preserving the overall B-cell compartment and its normal immune functions.